神经保护临床试验中动脉内治疗患者的选择标准
本研究旨在为正在进行的神经保护剂临床试验(RHAPSODY)制定动脉内神经血栓切除术(IAT)的患者选择标准,以探索在神经保护试验中纳入IAT的可行性。通过收集各试验中心的IAT选择标准并由专家小组审查,最终制定了试验的IAT选择标准。2015年6月15日实施允许IAT的方案修正案后,招募率从1.3%提升至6.2%(OR 4.9,95%CI 2.3-10.4,P<0.001)。
要点
- 在神经保护剂试验中纳入IAT是可行的。
- 制定的IAT选择标准与已发表证据一致。
- 放宽IAT标准后招募率显著提高。
核心结论
- 在急性缺血性卒中神经保护剂试验中纳入IAT是可行的。
- 所提出的IAT患者选择标准与已发表的IAT证据一致,同时保留测试神经保护剂疗效的能力。
研究设计与样本
- 研究药物3K3A-APC是一种多效细胞保护剂,可能减少溶栓相关出血。
- NeuroNEXT试验NN104(RHAPSODY)旨在确定3K3A-APC的最大耐受剂量。
- 每个试验中心提供其IAT选择标准,专家小组审查中心标准和已发表证据,最终由试验领导层设计IAT选择标准。
主要发现
- 制定的选择标准反映了各中心之间的一致性以及与已发表IAT试验的可比性。
- 允许IAT的方案修正案(放宽年龄、NIHSS和时间限制)于2015年6月15日实施。
- 修正案实施前招募8例患者(筛选601例,1.3%),实施后招募51例患者(筛选821例,6.2%)。
- 招募改善的比值比(95%置信限)为4.9(2.3-10.4),P<0.001。
- 修正案实施前后,每月每中心招募患者数分别为0.11例和0.43例。
关键数值与推荐
- 允许IAT的方案修正案放宽了年龄、美国国立卫生研究院卒中量表(NIHSS)评分和时间限制。
- 招募率从修正案前的1.3%提高到修正案后的6.2%(OR 4.9,95%CI 2.3-10.4,P<0.001)。
临床怎么用
- 在神经保护剂临床试验中可考虑纳入接受IAT的患者,以加速招募并提高试验效率。
- 制定IAT选择标准时应参考各中心实践和已发表证据,确保与现有证据一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: The advent of intra-arterial neurothrombectomy (IAT) for acute ischemic stroke opens a potentially transformative opportunity to improve neuroprotection studies. Combining a putative neuroprotectant with recanalization could produce more powerful trials but could introduce heterogeneity and adverse event possibilities. We sought to demonstrate feasibility of IAT in neuroprotectant trials by defining IAT selection criteria for an ongoing neuroprotectant clinical trial. METHODS: The study drug, 3K3A-APC, is a pleiotropic cytoprotectant and may reduce thrombolysis-associated hemorrhage. The NeuroNEXT trial NN104 (RHAPSODY) is designed to establish a maximally tolerated dose of 3K3A-APC. Each trial site provided their IAT selection criteria. An expert panel reviewed site criteria and published evidence. Finally, the trial leadership designed IAT selection criteria. RESULTS: Derived selection criteria reflected consistency among the sites and comparability to published IAT trials. A protocol amendment allowing IAT (and relaxed age, National Institutes of Health Stroke Scale, and time limits) in the RHAPSODY trial was implemented on June 15, 2015. Recruitment before and after the amendment improved from 8 enrolled patients (601 screened, 1.3%) to 51 patients (821 screened, 6.2%; odds ratio [95% confidence limit] of 4.9 [2.3-10.4]; P<0.001). Gross recruitment was 0.11 patients per site month versus 0.43 patients per site per month, respectively, before and after the amendment. CONCLUSIONS: It is feasible to include IAT in a neuroprotectant trial for acute ischemic stroke. Criteria are presented for including such patients in a manner that is consistent with published evidence for IAT while still preserving the ability to test the role of the putative neuroprotectant. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT02222714.
引用
- Lyden P, Weymer S, Coffey C, et al. Selecting Patients for Intra-Arterial Therapy in the Context of a Clinical Trial for Neuroprotection. Stroke. 2016. PMID: 27803392
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。